Additional file 1 of Effect of intermittent Pringle maneuver on perioperative outcomes and long-term survival following liver resection in patients with hepatocellular carcinoma: a meta-analysis and systemic review

Additional file 1: Supplementary Material 1. Search strategy. Supplementary Material 2. Risk assessment of RCT. Supplementary Material 3. NOS score of non-RCT studies. Supplementary Material 4. Subgroup analysis for overall survival and disease-free survival. Supplementary Material 5. Sensitivity analyses for overall survival and disease-free survival. Supplementary Material 6. Funnel plot for overall survival and disease-free survival. A, overall survival; B, disease-free survival. Supplementary Material 7. The effect of publication bias evaluated by using the trim and fill method for overall survival and disease-free survival. Supplementary Material 8. Forest plot after trimming and filling for overall survival and disease-free survival. Supplementary Material 9. Forest plot of sensitivity analysis for blood loss. Supplementary Material 10. Forest plot for blood loss after omitting the study by Fumularo et al. Supplementary Material 11. Forest plot of sensitivity analysis for blood loss after omitting the study by Fumularo et al. Supplementary Material 12. Forest plot of subgroup analysis based on the proportion of patients with Child A, the cut value was 90%. A, operation time; B, blood loss; C, blood transfusion; D, total complication; E, pleural effusion; F, hospital stay. Supplementary Material 13. Forest plot of subgroup analysis based on the proportion of patients with liver cirrhosis, the cut value was 70% for operation time and blood transfusion, while 60% for the rest. A, operation time; B, blood loss; C, blood transfusion; D, total complication; E, pleural effusion; F, ascites; G, hospital stay. Supplementary Material 14. Forest plot of subgroup analysis based on the proportion of patients received major liver resection, the cut value were 40% and 60% for blood loss, while 40% for the reset. A, operation time; B, blood loss; C, blood transfusion; D, total complication; E, hospital stay. Supplementary Material 15. Forest plot of subgroup analysis based on the proportion of patients with multiple tumor, the cut value was 25% for operation time and blood transfusion, while 60% for the rest. A, operation time; B, blood loss; C, blood transfusion; D, total complication; E, pleural effusion; F, hospital stay

DataSheet_1_Does perioperative allogeneic blood transfusion worsen the prognosis of patients with hepatocellular carcinoma? A meta-analysis of propensity score-matched studies.docx

BackgroundAllogeneic blood transfusion is required in a part of liver resection. The effect of allogeneic blood transfusion on the prognosis of patients with hepatocellular carcinoma (HCC) remains controversial. To investigate whether perioperative allogeneic blood transfusion (PBT) affects the long-term prognosis of patients with HCC, we conducted a meta-analysis that included only propensity score-matched (PSM) studies.MethodsThe Cochrane Library, Embase, PubMed, and Web of Science databases were systematically searched to identify PSM studies that compared the long-term outcomes of allogeneic blood transfusion in resected HCC patients. Overall survival (OS) and recurrence-free survival (RFS) rates were calculated.ResultsThis meta-analysis included 9 PSM studies with 12 datasets involving 2476 patients. Lower OS and RFS in HCC patients receiving allogeneic blood transfusion were observed than those in patients not receiving blood transfusion (OS: hazard ratio [HR], 1.34; 95% confidence interval [CI], 1.10–1.64; p ConclusionThe receipt of perioperative allogeneic blood transfusion is associated with a decrease in OS and RFS. These results seem to be reliable for patients in BCLC stage A. But more high-quality research is needed to confirm this conclusion.</p

Additional file 1 of Efficacy of transarterial therapy combined with first-line tyrosine kinase inhibitors for unresectable hepatocellular carcinoma: a network meta-analysis

Additional file 1: Supplementary Material S1. Results of full search strategy of database. Supplementary Material S2. Characteristics of included studies in this analysis. Supplementary Material S3. Additional information of characteristics of included studies in this analysis. Supplementary Material S4. Treatment ranking probability in patients with unresectable HCC. Supplementary Material S5. Ranking probabilities of outcomes in the studies.The dark-to-light color indicates the order of the rank. Dark color reflects a better PFS and TTP, lower AE, and higher ORR(mRECIST), DCR(mRECIST), ORR(RECIST), and DCR(RECIST). The size of the bar is proportional to the probability of interventions in each treatment. Supplementary Material S6. Quality assessment of the included studies. Supplementary Material S7. Results of global inconsistency analysis. Supplementary Material S8. Results of convergence. Supplementary Material S9. Results of publication bias (the Funnel Plot of Enrolled Trials). Supplementary Material S10. Node-splitting method for assessing local inconsistency between direct and indirect evidence. Supplementary Material S11. Heterogeneity. Supplementary Material S12. Forest plot of the outcomes. Supplementary Material S13. Forest plot of the outcomes (compared with sorafenib). Supplementary Material S14. Results of meta regression for OS

Additional file 1 of Does adjuvant hepatic artery infusion chemotherapy improve patient outcomes for hepatocellular carcinoma following liver resection? A meta-analysis

Additional file 1: Supplementary materials 1. Search strategy. Supplementary materials 2. The differences of included studies between our and previous studies. Supplementary materials 3. Risk assessment of RCTs. Supplementary materials 4. Plot of publication bias. Supplementary materials 5. Plot of sensitivity analysis. Supplementary materials 6. Plot of OS and DFS after omitting some studies. Supplementary materials 7. GRADE analysis of OS and DFS in the HAIC group

Additional file 1 of Comparison of liver resection and radiofrequency ablation in long-term survival among patients with early-stage hepatocellular carcinoma: a meta-analysis of randomized trials and high-quality propensity score-matched studies

Additional file 1 PRISMA checklis

Additional file 2 of Comparison of liver resection and radiofrequency ablation in long-term survival among patients with early-stage hepatocellular carcinoma: a meta-analysis of randomized trials and high-quality propensity score-matched studies

Additional file 2 Supplementary material: Supplementary material S1: Search strategy. Supplementary material S2 NOS score for PSM studies. Supplementary material S3 Risk bias of RCTs. Supplementary material S4 1-,3-,and 5-year survival rate, disease-free survival rate, and recurrence rate. Supplementary material S5 Forest plot for sensitivity analysis of overall survival and disease-free survival. Supplementary material S6 Funnel plot for overall survival and disease-free survival. Supplementary material S7 Meta-regression. OS, overall survival; DFS, disease-free survival; RFA, radiofrequency ablation. Supplementary material S8 Subgroup analysis for OS and DFS based on modality of RF

Kaplan-Meier analysis of DFS according to GATA2 SNP rs2335052.

<p>Kaplan-Meier curves are shown for an additive <b>(A)</b>, dominant <b>(B)</b>, and recessive model <b>(C)</b> of inheritance. The log-rank test was used to calculate <i>P</i> values.</p

GATA2 rs2335052 Polymorphism Predicts the Survival of Patients with Colorectal Cancer

<div><p>Background</p><p>GATA binding protein 2 (GATA2) is a transcription factor that has essential roles in hematologic malignancies and progression of various solid tumors. Our previous studies suggested that high GATA2 expression is associated with recurrence of colorectal cancer (CRC). However, the influence of GATA2 single nucleotide polymorphisms (SNPs) on the survival of CRC remains unknown.</p><p>Methods</p><p>We genotyped GATA2 SNP rs2335052 using Sanger sequencing after PCR amplification, and determined GATA2 expression by immunohistochemistry in a cohort of 180 CRC patients. Kaplan-Meier survival analysis and Cox proportional hazard regression were used to analyze the association between the GATA2 rs2335052 genotypes and the clinical outcome of CRC.</p><p>Results</p><p>We found that there was no significant correlation between the rs2335052 genotypes and the expression of GATA2. However, the Kaplan-Meier survival analysis suggested that the carriers of the A-allele of SNP rs2335052 were significantly associated with increased risk of recurrence and reduced disease-free survival (DFS), compared with those carrying the variant genotype of GG in rs2335052 (<i>P</i> = 0.021). Moreover, univariate and multivariate Cox regression analyses revealed that GATA2 SNP rs2335052 was an independent risk factor for the DFS of CRC patients.</p><p>Conclusion</p><p>Our results demonstrated that GATA2 SNP rs2335052 is an independent predictor for prognosis of CRC patients. This raised the possibility that SNP rs2335052 may serve as a potential indicator for predicting recurrence of CRC after curative colectomy.</p></div

Kaplan-Meier analysis of DFS according to GATA2 expression.

<p><b>(A)</b> Kaplan-Meier survival curve showed DFS for patients with GATA2-high tumors versus patients with GATA2-low tumors. Kaplan-Meier survival curves showed DFS for patients stratified by GATA2 rs2335052 GG <b>(B)</b>, and GG+AA <b>(C)</b> genotypes. The log-rank test was used to calculate <i>P</i> values.</p

Univariate and multivariate analyses of GATA2 rs2335052 genotypes in CRC patients with respect to DFS.

<p><i>HR</i> hazard ratio, <i>CI</i> confidence interval, <i>P</i> values in bold were statistically significant.</p><p>Univariate and multivariate analyses of GATA2 rs2335052 genotypes in CRC patients with respect to DFS.</p